Treatment of acute myeloid leukaemia with cytosine arabinoside and daunomycin in combination.
D000328:Adult; D000368:Aged; D001228:Aspergillosis / Q000209:etiology; D001424:Bacterial Infections / Q000209:etiology; D002177:Candidiasis / Q000209:etiology; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use*; D003630:Daunorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012075:Remission, Spontaneous; D013997:Time Factors
D003561:Cytarabine; D003630:Daunorubicin